Collegium Pharmaceutical Stock Performance

COLL Stock  USD 45.93  0.79  1.75%   
The firm shows a Beta (market volatility) of 0.78, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Collegium Pharmaceutical's returns are expected to increase less than the market. However, during the bear market, the loss of holding Collegium Pharmaceutical is expected to be smaller as well. Collegium Pharmaceutical right now shows a risk of 2.11%. Please confirm Collegium Pharmaceutical downside variance, and the relationship between the sortino ratio and accumulation distribution , to decide if Collegium Pharmaceutical will be following its price patterns.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Collegium Pharmaceutical has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent essential indicators, Collegium Pharmaceutical is not utilizing all of its potentials. The latest stock price mess, may contribute to short-term losses for the institutional investors. ...more

Actual Historical Performance (%)

One Day Return
(3.44)
Five Day Return
(4.93)
Year To Date Return
(0.86)
Ten Year Return
137.08
All Time Return
267.29
1
1 Small-Cap Stock with Exciting Potential and 2 We Avoid - The Globe and Mail
11/24/2025
2
Disposition of 17600 shares by Scott Dreyer of Collegium Pharmaceutical at 15.9 subject to Rule 16b-3
12/08/2025
3
Strong Q3 Beat and Guidance Upside Might Change The Case For Investing In Collegium Pharmaceutical
12/17/2025
4
Heres Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio
01/02/2026
5
How Collegiums New 980 Million Credit Facility Could Reshape Collegium Pharmaceutical Investors Risk Lens
01/08/2026
6
What 6 Analyst Ratings Have To Say About Collegium Pharmaceutical
01/09/2026
7
Is Collegium Pharmaceutical Stock Undervalued Right Now
01/12/2026
8
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference
01/15/2026
9
Universal Beteiligungs und Servicegesellschaft mbH Cuts Stock Position in Collegium Pharmaceutical, Inc. COLL - MarketBeat
01/29/2026
10
AlphaQuest LLC Purchases 15,769 Shares of Collegium Pharmaceutical, Inc. COLL
02/03/2026
11
The Truth About Collegium Pharmaceutical Quiet Stock, Loud Moves Are You Sleeping On Thi - AD HOC NEWS
02/11/2026
Begin Period Cash Flow240 M
Total Cashflows From Investing Activities-287.8 M

Collegium Pharmaceutical Relative Risk vs. Return Landscape

If you would invest  4,598  in Collegium Pharmaceutical on November 14, 2025 and sell it today you would lose (5.00) from holding Collegium Pharmaceutical or give up 0.11% of portfolio value over 90 days. Collegium Pharmaceutical is currently generating 0.0202% in daily expected returns and assumes 2.11% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than Collegium, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Collegium Pharmaceutical is expected to generate 5.19 times less return on investment than the market. In addition to that, the company is 2.73 times more volatile than its market benchmark. It trades about 0.01 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.14 per unit of volatility.

Collegium Pharmaceutical Target Price Odds to finish over Current Price

The tendency of Collegium Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 45.93 90 days 45.93 
about 68.24
Based on a normal probability distribution, the odds of Collegium Pharmaceutical to move above the current price in 90 days from now is about 68.24 (This Collegium Pharmaceutical probability density function shows the probability of Collegium Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Collegium Pharmaceutical has a beta of 0.78 suggesting as returns on the market go up, Collegium Pharmaceutical average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Collegium Pharmaceutical will be expected to be much smaller as well. Additionally Collegium Pharmaceutical has an alpha of 0.1011, implying that it can generate a 0.1 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Collegium Pharmaceutical Price Density   
       Price  

Predictive Modules for Collegium Pharmaceutical

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Collegium Pharmaceutical. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
43.0145.1347.25
Details
Intrinsic
Valuation
LowRealHigh
40.6349.8451.96
Details
5 Analysts
Consensus
LowTargetHigh
48.8453.6759.57
Details
Earnings
Estimates (0)
LowProjected EPSHigh
1.471.621.84
Details

Collegium Pharmaceutical Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Collegium Pharmaceutical is not an exception. The market had few large corrections towards the Collegium Pharmaceutical's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Collegium Pharmaceutical, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Collegium Pharmaceutical within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.10
β
Beta against Dow Jones0.78
σ
Overall volatility
1.75
Ir
Information ratio 0.04

Collegium Pharmaceutical Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Collegium Pharmaceutical for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Collegium Pharmaceutical can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Collegium Pharmaceutical currently holds 859.3 M in liabilities with Debt to Equity (D/E) ratio of 3.82, implying the company greatly relies on financing operations through barrowing. Collegium Pharmaceutical has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Collegium Pharmaceutical's use of debt, we should always consider it together with its cash and equity.
Over 98.0% of Collegium Pharmaceutical shares are held by institutions such as insurance companies
Latest headline from news.google.com: The Truth About Collegium Pharmaceutical Quiet Stock, Loud Moves Are You Sleeping On Thi - AD HOC NEWS

Collegium Pharmaceutical Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Collegium Stock often depends not only on the future outlook of the current and potential Collegium Pharmaceutical's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Collegium Pharmaceutical's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding40.4 M
Cash And Short Term Investments162.8 M

Collegium Pharmaceutical Fundamentals Growth

Collegium Stock prices reflect investors' perceptions of the future prospects and financial health of Collegium Pharmaceutical, and Collegium Pharmaceutical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Collegium Stock performance.

About Collegium Pharmaceutical Performance

By examining Collegium Pharmaceutical's fundamental ratios, stakeholders can obtain critical insights into Collegium Pharmaceutical's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Collegium Pharmaceutical is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 58.74  55.80 
Return On Tangible Assets 0.10  0.11 
Return On Capital Employed 0.13  0.14 
Return On Assets 0.04  0.04 
Return On Equity 0.27  0.29 

Things to note about Collegium Pharmaceutical performance evaluation

Checking the ongoing alerts about Collegium Pharmaceutical for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Collegium Pharmaceutical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Collegium Pharmaceutical currently holds 859.3 M in liabilities with Debt to Equity (D/E) ratio of 3.82, implying the company greatly relies on financing operations through barrowing. Collegium Pharmaceutical has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Collegium Pharmaceutical's use of debt, we should always consider it together with its cash and equity.
Over 98.0% of Collegium Pharmaceutical shares are held by institutions such as insurance companies
Latest headline from news.google.com: The Truth About Collegium Pharmaceutical Quiet Stock, Loud Moves Are You Sleeping On Thi - AD HOC NEWS
Evaluating Collegium Pharmaceutical's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Collegium Pharmaceutical's stock performance include:
  • Analyzing Collegium Pharmaceutical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Collegium Pharmaceutical's stock is overvalued or undervalued compared to its peers.
  • Examining Collegium Pharmaceutical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Collegium Pharmaceutical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Collegium Pharmaceutical's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Collegium Pharmaceutical's stock. These opinions can provide insight into Collegium Pharmaceutical's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Collegium Pharmaceutical's stock performance is not an exact science, and many factors can impact Collegium Pharmaceutical's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.
When determining whether Collegium Pharmaceutical is a strong investment it is important to analyze Collegium Pharmaceutical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Collegium Pharmaceutical's future performance. For an informed investment choice regarding Collegium Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Collegium Pharmaceutical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.
You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. Projected growth potential of Collegium fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Collegium Pharmaceutical assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth
2.132
Earnings Share
1.63
Revenue Per Share
23.798
Quarterly Revenue Growth
0.314
Return On Assets
0.0675
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Collegium Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Collegium Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Collegium Pharmaceutical's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.